Need professional-grade analysis? Visit stockanalysis.com
$48.53B
46.17
16,000
N/A
Price Chart
Risk-Adjusted Performance
Edwards Lifesciences Corp (EW) Price Performance
Edwards Lifesciences Corp (EW) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at $82.50, down 0.13% from the previous close.
Over the past year, EW has traded between a low of $67.07 and a high of $87.18. The stock has gained 15.8% over this period. It is currently 5.4% below its 52-week high.
Edwards Lifesciences Corp has a market capitalization of $48.53B, with a price-to-earnings ratio of 46.17.
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Company Info
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $5.01B
- EBITDA
- $1.79B
- Profit Margin
- 17.69%
- EPS (TTM)
- 2.33
- Book Value
- 17.80
Technical Indicators
- 52 Week High
- $87.89
- 52 Week Low
- $65.94
- 50 Day MA
- $82.63
- 200 Day MA
- $80.28
- Beta
- 0.93
Valuation
- Trailing P/E
- 46.17
- Forward P/E
- 28.49
- Price/Sales
- 8.00
- Price/Book
- 4.60
- Enterprise Value
- $50.04B